India Pharmaceutical major Wockhardt Limited has signed an in-licensing pact with UK-based Sinclair Pharma, to market a range of dermatology and dental products in Indian market. 

The 10-year exclusivity agreement covers a broad range of patented and innovative products, including Papulex, Atopiclair, Aloclair and Decapinol range. 

Further, the agreement also envisages that Wockhardt manufacture the formulation in India from bulk imported from Sinclair Pharma. 

Sinclair Pharma plc is an international specialty pharmaceutical firm having subsidiaries in France, Italy, Spain, and Portugal with operations spanning across 82 countries. 

Apart from latest move, the company is also in talks with Sinclair on contract manufacturing of the signed products for their European markets and to bring in to India the next phase of dermatology products from the Sinclair stable.

According to market experts, this deal is a further step towards Wockhardt’s strategy of consolidating its position in dermatology and focus in dentistry.